ATE227996T1 - Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod - Google Patents

Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod

Info

Publication number
ATE227996T1
ATE227996T1 AT98938555T AT98938555T ATE227996T1 AT E227996 T1 ATE227996 T1 AT E227996T1 AT 98938555 T AT98938555 T AT 98938555T AT 98938555 T AT98938555 T AT 98938555T AT E227996 T1 ATE227996 T1 AT E227996T1
Authority
AT
Austria
Prior art keywords
composition
cell
regulating
dna
cell proliferation
Prior art date
Application number
AT98938555T
Other languages
German (de)
English (en)
Inventor
Nigel C Phillips
Mario C Fillion
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of ATE227996T1 publication Critical patent/ATE227996T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT98938555T 1997-08-05 1998-08-05 Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod ATE227996T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5477797P 1997-08-05 1997-08-05
US7506798P 1998-02-18 1998-02-18
US7511198P 1998-02-18 1998-02-18
US8631798P 1998-05-21 1998-05-21
PCT/CA1998/000744 WO1999007383A1 (en) 1997-08-05 1998-08-05 Composition and method for regulating cell proliferation and cell death

Publications (1)

Publication Number Publication Date
ATE227996T1 true ATE227996T1 (de) 2002-12-15

Family

ID=27489673

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98938555T ATE227996T1 (de) 1997-08-05 1998-08-05 Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod

Country Status (17)

Country Link
US (2) US6329347B1 (enExample)
EP (1) EP1003525B1 (enExample)
JP (2) JP4335435B2 (enExample)
KR (1) KR100533576B1 (enExample)
AT (1) ATE227996T1 (enExample)
AU (1) AU736450B2 (enExample)
BR (1) BR9815602A (enExample)
CA (1) CA2299548C (enExample)
DE (1) DE69809561T2 (enExample)
DK (1) DK1003525T3 (enExample)
ES (1) ES2187047T3 (enExample)
HU (1) HU227921B1 (enExample)
IL (3) IL134371A0 (enExample)
NO (1) NO322450B1 (enExample)
NZ (1) NZ502674A (enExample)
PT (1) PT1003525E (enExample)
WO (1) WO1999007383A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2299548C (en) 1997-08-05 2009-12-29 Bioniche Inc. Composition and method for regulating cell proliferation and cell death
ES2238780T3 (es) * 1998-02-18 2005-09-01 Bioniche Life Sciences Inc. Tratamiento de cancer de vejiga mediante pared celular de mycobacterium phlei.
DE69920506T2 (de) * 1998-12-04 2005-10-13 Bioniche Life Sciences Inc., London Chemotherapeutische zusammensetzung und verfahren
US6809081B1 (en) * 1998-12-04 2004-10-26 Bioniche Life Sciences, Inc. Chemotherapeutic composition and method
EP1135164B1 (en) * 1998-12-04 2004-08-11 Bioniche Life Sciences Inc. Composition for the treatment of inflammation
ES2238996T3 (es) * 1999-04-01 2005-09-16 Bioniche Life Sciences Inc. Composicion y metodo para inducir apoptosis en celulas de cancer de prostata.
US6794368B1 (en) * 1999-04-01 2004-09-21 Bioniche Life Sciences Inc. Composition and method for inducing apoptosis in prostate cancer cells
WO2000061597A1 (en) 1999-04-08 2000-10-19 Uab Research Foundation Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
WO2001022979A1 (en) * 1999-09-29 2001-04-05 Bioniche Life Sciences Inc. Method to disrupt mitochondrial function
CZ20022372A3 (cs) * 1999-12-13 2002-11-13 Bioniche Life Sciences Inc. Terapeuticky pouľitelné syntetické oligonukleotidy
CA2395493C (en) 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
US6673566B1 (en) 2002-01-10 2004-01-06 The United States Of America As Represented By The Secretary Of Agriculture Diagnosis of pathogen infections through analysis of nitrite production by antigen stimulated leukocytes
KR101400105B1 (ko) * 2006-07-25 2014-06-19 리폭센 테크놀로지즈 리미티드 N-말단 폴리시알화
AR083443A1 (es) 2010-10-13 2013-02-27 Bioniche Life Sciences Inc Una composicion que comprende arn bacteriano y paredes celulares bacterianas, metodo para elaborar dicha composicion y sus usos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
FR2160326B1 (enExample) 1971-11-19 1975-02-07 Anvar
US4152423A (en) 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
CA1020460A (en) 1973-02-23 1977-11-08 Wellcome Foundation Limited (The) Isolation of immunostimulating glycopeptide from bacteria
US3976544A (en) 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
BR9406496A (pt) 1993-01-29 1996-01-02 Vetrepharm Inc Processo e composição para estimulação do sistema imunológico em um ser humano ou animal
CA2299548C (en) 1997-08-05 2009-12-29 Bioniche Inc. Composition and method for regulating cell proliferation and cell death

Also Published As

Publication number Publication date
NZ502674A (en) 2002-06-28
WO1999007383B1 (en) 1999-03-25
KR100533576B1 (ko) 2005-12-05
AU8723698A (en) 1999-03-01
NO20000576L (no) 2000-04-04
IL134371A (en) 2007-07-24
JP2001513504A (ja) 2001-09-04
IL134371A0 (en) 2001-04-30
DK1003525T3 (da) 2003-03-24
IL180924A (en) 2010-11-30
CA2299548A1 (en) 1999-02-18
US6329347B1 (en) 2001-12-11
HUP0003012A2 (hu) 2000-12-28
JP2008208140A (ja) 2008-09-11
CA2299548C (en) 2009-12-29
NO20000576D0 (no) 2000-02-04
AU736450B2 (en) 2001-07-26
WO1999007383A1 (en) 1999-02-18
JP4335435B2 (ja) 2009-09-30
EP1003525A1 (en) 2000-05-31
NO322450B1 (no) 2006-10-09
HU227921B1 (hu) 2012-06-28
ES2187047T3 (es) 2003-05-16
BR9815602A (pt) 2001-12-11
HUP0003012A3 (en) 2004-03-29
DE69809561D1 (de) 2003-01-02
PT1003525E (pt) 2003-03-31
EP1003525B1 (en) 2002-11-20
DE69809561T2 (de) 2003-09-25
IL180924A0 (en) 2007-07-04
US6326357B1 (en) 2001-12-04
KR20010022643A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
IL180924A (en) Method for regulating cell proliferation and cell death
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
AU3649397A (en) Precise efficacy assay methods for active agents including chemotherapeutic agents
DE69637726D1 (de) Gruppen zum einfangen von nukleinsäuren
AU1926899A (en) Exploiting genomics in the search for new drugs
NL7610984A (nl) Werkwijze voor het bestuderen van enzymatische andere biochemische reacties.
DK0389063T3 (da) Fremgangsmåde til isolering af nukleinsyre
EP0599651A3 (en) Bioreactor for cell culture in perfusion.
DE69836491D1 (de) Fibrinmikrokugeln und deren verwendungen
TR199800046A2 (xx) Aktif maddeler yarat�lmas� i�in n�kleik asit olu�umu.
IT8820920A0 (it) Dispositivo di fermentazione per la coltura aerobica di microorganismi.
DE3676148D1 (de) Antigerinnungsmittel, verfahren zu seiner herstellung und dieses mittel als wirkender grundstoff enthaltende antikoagulantia.
ES2165368T3 (es) Cultivo de celulas animales.
IL148152A0 (en) Sequence-specific dna recombination in eukaryotic cells
NL7808970A (nl) Werkwijze en inrichting voor het uitvoeren van electro- chemische reacties alsmede daarvoor geschikte bipolaire electroden.
FI886050A7 (fi) Amperometrinen menetelmä 1,4-dihydronikotiiniamidiadeniinidinukleotidin (NADH) kvantitatiiviseksi määrittämiseksi liuoksessa
ES8403157A1 (es) Un metodo de preparar sustancias biologicamente activas que tienen actividad anti-tumoral.
DK0572120T3 (da) Nucleinsyre-probertil mycobacterium tuberculosis
TW229232B (enExample)
IT8721047A0 (it) Dispositivo per culture microbiologiche.
ATE302264T1 (de) Freigabe von intrazellulärem material
IT8819768A0 (it) Dispositivo perfezionato perl'esecuzione di esami microbiologici colturali.
HUP0102413A1 (hu) Vektorok nukleinsavak bevitelére, ezeket tartalmazó készítmények és alkalmazásuk
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
DE3783399D1 (de) Verfahren fuer biologische reaktionen mittels an traegern immobilisierten zellen und vorrichtung zur durchfuehrung des verfahrens.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1003525

Country of ref document: EP